Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 7/20 | 0.39 |
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28719542 | 0.85 | TSHR (0.43) | OPRM1OPRK1OPRL1MAOBMAOA | |
| SCHEMBL9543164 | 0.82 | TACR1 (0.36) | OPRM1OPRK1OPRL1MEN1KMT2A | |
| SCHEMBL22436670 | 0.77 | OPRM1 (0.42) | OPRM1OPRK1OPRL1MAOBMAOA | |
| SCHEMBL1610186 | 0.71 | OPRM1 (0.42) | OPRM1OPRK1OPRL1MAOBMAOA | |
| SCHEMBL6426369 | 0.71 | MAOB (0.46) | OPRM1OPRK1OPRL1MAOBMAOA | |
| SCHEMBL2283117 | 0.69 | HDAC4 (0.34) | OPRM1OPRK1OPRL1MAOBMAOA | |
| SCHEMBL10876622 | 0.65 | OPRM1 (0.41) | OPRM1OPRK1OPRL1MAOBMAOA | |
| SCHEMBL5480380 | 0.65 | OPRM1 (0.41) | OPRM1OPRK1OPRL1MAOBMAOA | |
| SCHEMBL2256573 | 0.65 | OPRM1 (0.67) | OPRM1OPRK1OPRL1MAOBMAOA | |
| SCHEMBL18662200 | 0.65 | OPRM1 (0.52) | OPRM1OPRK1OPRL1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110128270-B | 2, 2-diphenyl cyclopropyl compound and synthetic method thereof | 郑州手性药物研究院有限公司 | 2022-05-24 | — | — | CN | claimed |
| CN-110128270-B | 2, 2-diphenyl cyclopropyl compound and synthetic method thereof | 郑州手性药物研究院有限公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-110128270-B | 2, 2-diphenyl cyclopropyl compound and synthetic method thereof | 郑州手性药物研究院有限公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-110128270-B | 2, 2-diphenyl cyclopropyl compound and synthetic method thereof | 郑州手性药物研究院有限公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-110128341-A | A kind of chiral 2,2 '-bipyridine ligand and preparation method thereof and preparing the application in chiral cyclopropane derivative | 西安交通大学 | 2019-08-16 | — | — | CN | disclosed |
| CN-110128270-A | 2,2- hexichol cyclopropyl class compound and its synthetic method | 郑州手性药物研究院有限公司 | 2019-08-16 | — | — | CN | disclosed |
| US-20150065738-A1 | PHOSPHOROUS COMPOUND AND TRANSITION METAL COMPLEX THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2842959-A1 | Phosphorous compound and transition metal complex thereof | Takasago International Corporation (JP) | 2015-03-04 | — | — | EP | disclosed |
| EP-1910307-A1 | PYRAZOLE BASED LXR MODULATORS | Exelixis, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-0581789-A1 | NOVEL 2-SPIROCYCLOPROPYL CEPHALOSPORIN SULFONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | SYNPHAR LABORATORIES INC. (CA) | 1994-02-09 | — | — | EP | disclosed |
| WO-1993015100-A1 | NOVEL ADENOSINE DERIVATIVES, THEIR PREPARATION METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LABORATOIRES UPSA (FR) | 1993-08-05 | — | — | WO | disclosed |
| EP-0054917-A2 | 6- and 4-Substituted-1-azabicyclo(3.2.0)heptan-3,7-dione-2-carboxylates | MERCK & CO. INC. (US) | 1982-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065738-A1 | PHOSPHOROUS COMPOUND AND TRANSITION METAL COMPLEX THEREOF | AP2M1, AP1M1, APBA1 | OPRM1 1965/4885OPRK1 3548/4885OPRL1 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.